Review



bodipy fl c16  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Thermo Fisher bodipy fl c16
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 89935 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy fl c16/product/Thermo Fisher
    Average 99 stars, based on 89935 article reviews
    bodipy fl c16 - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "PD-L1 ligation on NK cells induces a metabolic shift from glycolysis to fatty acid oxidation, enhancing tumor infiltration and control"

    Article Title: PD-L1 ligation on NK cells induces a metabolic shift from glycolysis to fatty acid oxidation, enhancing tumor infiltration and control

    Journal: bioRxiv

    doi: 10.1101/2025.06.27.661921

    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and Bodipy FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Figure Legend Snippet: (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and Bodipy FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .

    Techniques Used: RNA Sequencing, Expressing, Cell Culture, Lysis



    Similar Products

    bodipy fl c16  (Thermo Fisher)
    99
    Thermo Fisher bodipy fl c16
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy fl c16/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    bodipy fl c16 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    bodipy fl c16  (MedChemExpress)
    93
    MedChemExpress bodipy fl c16
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy fl c16/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    bodipy fl c16 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    bodipy-fl-c16 d3821  (Thermo Fisher)
    90
    Thermo Fisher bodipy-fl-c16 d3821
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16 D3821, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy-fl-c16 d3821/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    bodipy-fl-c16 d3821 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bodipy-fl-c16  (Thermo Fisher)
    90
    Thermo Fisher bodipy-fl-c16
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy-fl-c16/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    bodipy-fl-c16 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bodipy-fl-c16 probe 1:2,500  (Thermo Fisher)
    90
    Thermo Fisher bodipy-fl-c16 probe 1:2,500
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16 Probe 1:2,500, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy-fl-c16 probe 1:2,500/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    bodipy-fl-c16 probe 1:2,500 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    4,4- difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (bodipy fl c16)  (Thermo Fisher)
    90
    Thermo Fisher 4,4- difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (bodipy fl c16)
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    4,4 Difluoro 5,7 Dimethyl 4 Bora 3a,4a Diaza S Indacene 3 Hexadecanoic Acid (Bodipy Fl C16), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/4,4- difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (bodipy fl c16)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    4,4- difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-hexadecanoic acid (bodipy fl c16) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bodipy fl c16 (4,4-difluoro-5,7-dimethyl-4bora-3a,4a-diaza-s-indacene3-hexadecanoic acid)  (Thermo Fisher)
    90
    Thermo Fisher bodipy fl c16 (4,4-difluoro-5,7-dimethyl-4bora-3a,4a-diaza-s-indacene3-hexadecanoic acid)
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16 (4,4 Difluoro 5,7 Dimethyl 4bora 3a,4a Diaza S Indacene3 Hexadecanoic Acid), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy fl c16 (4,4-difluoro-5,7-dimethyl-4bora-3a,4a-diaza-s-indacene3-hexadecanoic acid)/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    bodipy fl c16 (4,4-difluoro-5,7-dimethyl-4bora-3a,4a-diaza-s-indacene3-hexadecanoic acid) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bodipy fl c16 bodipy-c16  (Thermo Fisher)
    90
    Thermo Fisher bodipy fl c16 bodipy-c16
    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and <t>Bodipy</t> FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .
    Bodipy Fl C16 Bodipy C16, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bodipy fl c16 bodipy-c16/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    bodipy fl c16 bodipy-c16 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and Bodipy FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .

    Journal: bioRxiv

    Article Title: PD-L1 ligation on NK cells induces a metabolic shift from glycolysis to fatty acid oxidation, enhancing tumor infiltration and control

    doi: 10.1101/2025.06.27.661921

    Figure Lengend Snippet: (A, B) RNA sequencing analysis was performed on ctNK cells alone or ctNK cells treated with AZ overnight. (A) Selected enrichment plots from pathway analysis. (n=5 healthy human donors) (B) Relative expression of DE genes involved in glycolysis or metabolism of fatty acids. (C, D) ctNK cells alone and ctNK cells treated with AZ or sPD-1 overnight were assessed for the expression of Cpt1a (n=12) (C) and Bodipy FLC-16 (n=12) and Bodipy 493/503 (n=6) uptake (D) and normalized to each donor. (E-G) PD-L1 -/- B16F10 were administered into flanks of NK-specific CPT1a -/- mice or their WT littermates. Mice were treated with AZ or PBS intraperitoneally three times a week. (F) Weight of resected PD-L1 -/- B16F10 tumors. (n=4 mice per group) (G) Tumor volume was measured at regular time points, as indicated. (H, I) Extracellular acidification rate (ECAR) was measured in ctNK. (n=6) (I) Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the ECAR curve and normalized to each donor. (J) The expression of MTOR (left) and SLC7A5 (right) gene in ctNK cells and ctNK cells treated with AZ overnight. (n=5) (K) gMFI of pS6 in ctNK or ctNK cells treated with the AZ or sPD-1 overnight normalized to each donor. (n=6) (L, M) ctNK were cultured in glucose-sufficient or glucose-depleted media overnight. The lysis of indicated AML cell lines was then assessed. (n=4) (M) The killing capacity of ctNK or ctNK treated with AZ or sPD-1 cultured in glucose-sufficient or glucose-depleted media of KG1 target cells was assessed. (n=4). Each symbol represents an individual human donor (C, D, I-L) or individual mouse (F). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 Friedman test (C, D, I, K), Kruskal-Wallis test (F), paired t-test (J, L), or two-way ANOVA (M). Error bars, mean ± range (C-F), or mean ± s.e.m (G-M). See also Figure S5, S6 .

    Article Snippet: PD-L1-expressing human NK cells were treated with atezolizumab or sPD-1 overnight and approximately 2 x 10^5 cells were plated and cultured with 2ng/ml BODIPY 493/503 (ThermoFisher), 10 ng/ml BODIPY FL C16 (ThermoFisher) for 30 min at 37°C in PBS, washed with FACS buffers, stained with surface antibodies, and analyzed by flow cytometry.

    Techniques: RNA Sequencing, Expressing, Cell Culture, Lysis